Memorial Sloan Kettering Cancer Center: Urinary Bladder Neoplasms trials

The registry lists 39 Urinary Bladder Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 10 have results posted.

Phase 1 8Phase 2 19Phase 3 4No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of a Side Effects and Resource Navigation Program for People With CancerRecruitingNCT07646847Not applicable
• A Study of Surgical Techniques During CystectomyRecruitingNCT06703476Phase 3
• A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueRecruitingNCT05837767Not applicable
• A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin CancerRecruitingNCT05562791Phase 1
• Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary TractCompletedNCT03430895Phase 2Results posted
• BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the BladderCompletedNCT02657486Not applicableResults posted
• Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)CompletedNCT02553642Phase 2Results posted
• Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder CancerCompletedNCT02281383Phase 2Results posted
• Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder CancerTerminatedNCT01916109Phase 2Results posted
• Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder CancerCompletedNCT01589094Phase 2Results posted
• Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer PatientsTerminatedNCT00974818Phase 3Results posted
• Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder CancerCompletedNCT00847015Phase 2Results posted
• Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain MetastasesCompletedNCT00587964Phase 2Results posted
• Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the UrotheliumCompletedNCT00397488Phase 2Results posted
• A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder CancerWithdrawnNCT07414992Phase 2
• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerActive, not recruitingNCT04917809Phase 2
• A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsActive, not recruitingNCT03693014Phase 2
• A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyActive, not recruitingNCT03520491Phase 2
• Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Active, not recruitingNCT03504163Phase 2
• A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerActive, not recruitingNCT02989584Phase 1/2
• Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersCompletedNCT02675829Phase 2
• Determinants of Bladder Cancer Recurrence Study (The DETER Study)Active, not recruitingNCT02400944
• IFACT: Incidental Findings in Advanced Cancer TherapyCompletedNCT02217891
• A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical CystectomyCompletedNCT02145871Phase 3
• Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine ChemotherapyCompletedNCT01104350Phase 1
• Randomized Trial Comparing Robotic and Open Radical CystectomyCompletedNCT01076387Phase 3
• A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder CancerTerminatedNCT00918008
• A Genotype-Phenotype Urothelial Cancer RegistryActive, not recruitingNCT00902590
• Quality of Life in Patients With Bladder CancerActive, not recruitingNCT00745355
• Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and StagingCompletedNCT00612326
• Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder CancerCompletedNCT00582387
• Germline Alterations of Tumor Susceptibility Genes in New York Cancer PatientsActive, not recruitingNCT00579514Not applicable
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
• Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney CancerCompletedNCT00003342Phase 1
• Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder CancerCompletedNCT00003133Phase 1
• Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder CancerCompletedNCT00003105Phase 1/2
• Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1/2
• Combination Chemotherapy in Treating Patients With Stage II Bladder CancerCompletedNCT00002919Phase 2
• Combination Chemotherapy in Patients With Advanced Urinary Tract CancerCompletedNCT00002684Phase 2